Fate Therapeutics (FATE) EBIT Margin Growth (3y) (2015 - 2026)

Fate Therapeutics (FATE) EBIT Margin Growth (3y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -50,506.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 Fate Therapeutics 298.82 Mn 298.82 Mn - -249,194.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -249,194.00
Dec 31, 2025 -239,100.00
Sep 30, 2025 -141,845.00
Jun 30, 2025 -149,049.00
Mar 31, 2025 -212,967.00
Dec 31, 2024 -291,331.00
Sep 30, 2024 -131,988.00
Jun 30, 2024 -31,694.00
Mar 31, 2024 -223,815.00
Dec 31, 2023 -265,833.00
Sep 30, 2023 -222,120.00
Jun 30, 2023 -618,050.00
Mar 31, 2023 132,297.00
Dec 31, 2022 89,253.00
Sep 30, 2022 53,980.00
Jun 30, 2022 40,690.00
Mar 31, 2022 37,242.00
Dec 31, 2021 60,141.00
Sep 30, 2021 124,291.00
Jun 30, 2021 156,017.00